- Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
- Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
- Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
More ▼
Key statistics
On Monday, Acumen Pharmaceuticals Inc (ABOS:NSQ) closed at 3.23, 78.44% above the 52 week low of 1.81 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.90 |
---|---|
High | 3.26 |
Low | 2.83 |
Bid | 3.23 |
Offer | 3.33 |
Previous close | 2.87 |
Average volume | 494.32k |
---|---|
Shares outstanding | 60.08m |
Free float | 53.33m |
P/E (TTM) | -- |
Market cap | 184.44m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼